Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 553.93M P/E 38.36 EPS this Y -550.00% Ern Qtrly Grth -
Income -16.55M Forward P/E 26.38 EPS next Y 77.80% 50D Avg Chg 10.00%
Sales 448.39M PEG -6.50 EPS past 5Y -39.97% 200D Avg Chg 46.00%
Dividend N/A Price/Book 2.10 EPS next 5Y 2.41% 52W High Chg -35.00%
Recommedations 2.00 Quick Ratio 2.29 Shares Outstanding 132.58M 52W Low Chg 135.00%
Insider Own 32.88% ROA 1.94% Shares Float 59.76M Beta 1.60
Inst Own 47.67% ROE -6.19% Shares Shorted/Prior 11.68M/10.93M Price 4.22
Gross Margin 75.14% Profit Margin -3.69% Avg. Volume 1,081,440 Target Price 4.38
Oper. Margin 6.84% Earnings Date Nov 7 Volume 746,556 Change -1.63%
About Organogenesis Holdings Inc.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Organogenesis Holdings Inc. News
11/22/24 Organogenesis Expands Manufacturing Capacity to Support Future Growth
11/15/24 Organogenesis Commends Final LCDs
11/13/24 Organogenesis Holdings Inc (ORGO) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
11/12/24 Organogenesis (ORGO) Q3 2024 Earnings Call Transcript
11/12/24 Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates
11/12/24 Organogenesis: Q3 Earnings Snapshot
11/12/24 Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results
11/12/24 Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock
11/11/24 Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
11/04/24 Organogenesis Holdings And 2 Other US Penny Stocks To Watch
10/30/24 Shareholders in Organogenesis Holdings (NASDAQ:ORGO) are in the red if they invested three years ago
10/16/24 Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024
10/01/24 Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers
09/04/24 Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September
08/10/24 Organogenesis Holdings Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
08/08/24 Organogenesis (ORGO) Q2 2024 Earnings Call Transcript
08/08/24 Organogenesis (ORGO) Reports Q2 Loss, Tops Revenue Estimates
08/08/24 Organogenesis: Q2 Earnings Snapshot
08/08/24 Organogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results
08/08/24 Organogenesis Shares ReNu® Program Update
ORGO Chatroom

User Image DonCorleone77 Posted - 7 hours ago

$ORGO Organogenesis expands manufacturing capacity to support future growth Organogenesis Holdings announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island. "We are pleased to join the Rhode Island life sciences community as we expand our New England manufacturing capacity to support future growth," said Gary S. Gillheeney, Sr., President, Chief Executive Officer, and Chair of the Board. "We look forward to strengthening our industry-leading portfolio with this world class biomanufacturing facility." The company will continue to operate its headquarters and manufacturing facilities in Canton, Mass., as well as additional operations in Norwood, Mass., Birmingham, Ala., San Diego, Calif., St. Petersburg, Fla., and Reinach, Switzerland. The Rhode Island lease is contingent upon anticipated state and local tax incentives.

User Image KadenSalas Posted - 3 days ago

$ORGO $TEM LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image josegodoy Posted - 1 week ago

$ORGO this puppy is gonna be grinding for awhile IMO - (nearer term) possible pullback to $3 area in my opinion, after that…. - liking $6-$7 area (longer term), what’s the catalyst?…..the market is uncertain with respect to this target range - still liking $12-$15 area, same as above….cat? - let’s see what happens An opinion

User Image UrethraFranklin Posted - 1 week ago

$ORGO That LCD final rule is a major disaster for them. Only 4 applications (without massive paperwork) and no VLUs. 60% reduction in current business.

User Image Mobagri Posted - 1 week ago

$ORGO when does the PuraPly RCT trial conclude?

User Image LongtimeStanding Posted - 1 week ago

$ORGO mew LCD is out. goes into effect on 2/14/25

User Image Mobagri Posted - 1 week ago

$ORGO as soon as MACS announce no changes this will hit $6 and all the shorts are Fckd

User Image 1UpOnWallStreet Posted - 1 week ago

$ORGO Good short if it goes above $4.75.

User Image Bio_Be_Dirty Posted - 1 week ago

$ORGO time to short

User Image Invest2live Posted - 1 week ago

$ORGO 80% already; congrats 🎉🎊🎈 Checkout $adbe, $CPRI and $SLB

User Image josegodoy Posted - 1 week ago

$ORGO the run may be done…we shall see

User Image josegodoy Posted - 1 week ago

$ORGO 😂😂

User Image Faddafin Posted - 1 week ago

$ORGO 👌👌👌👌👌👌

User Image Faddafin Posted - 1 week ago

$ORGO down?

User Image simonig1 Posted - 1 week ago

$ORGO @Mobagri Where does it say the directors are paying themselves 24 million dollars? The earnings announcement was very good and it was a very upbeat conference call. I saw the after-hours trading and it was up substantially. The last two trades after hours were 200 shares at 3.53 followed 3 minutes later with 2 shares at 3.36. Someone was just painting the tape to make it look bad.

User Image Mobagri Posted - 1 week ago

$ORGO why the F..are the directors paying themself 24 million dollars by diluting everyone’s share? That’s why the stock crashed instead of blowing up. Corruption

User Image Raiderdave98 Posted - 1 week ago

$ORGO private placement jacks us. Give me that deal. I’ll trade my common shares. Yuck diluted 19 mm shares

User Image DonCorleone77 Posted - 1 week ago

$ORGO Organogenesis sees FY24 revenue $455-$480M, consensus $456.15M Net revenue from Advanced Wound Care products between $429.0 million and $452.0 million, an increase of 6% to 11% year-over-year as compared to net revenue of $405.5 million for the year ended December 31 .

User Image DonCorleone77 Posted - 1 week ago

$ORGO Organogenesis reports Q3 EPS 9c, consensus (1c) Reports Q3 revenue $115.2M, consensus $108.83M."Our third quarter results underscore the strength of our portfolio and brand equity as customers select Organogenesis as their trusted partner while they navigate this complex market," said Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board for Organogenesis. "We continue to work with policy and lawmakers to craft a solution that addresses spending while ensuring access to safe and effective therapies for all patients, particularly those who are most vulnerable. We believe a resolution is on the horizon."

User Image Invest2live Posted - 1 week ago

$ORGO 65% already; congrats Check out $AMZN, $SLB, $CPRI and $LCTX

User Image simonig1 Posted - 1 week ago

$ORGO Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis CANTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the favorable outcome of the interim analysis of its second Phase 3 randomized control trial of ReNu, a cryopreserved amniotic suspension allograft (ASA), for the management of symptoms associated with knee osteoarthritis (OA). Link: https://finance.yahoo.com/news/organogenesis-reports-positive-interim-analysis-220500485.html

User Image simonig1 Posted - 1 week ago

$ORGO Organogenesis Holdings (ORGO) Receives a Buy from Lake StreetBlurbs Organogenesis Holdings (ORGO) Receives a Buy from Lake Street Ryan Adist Nov 11, 2024, 05:56 AM In a report released today, Brooks O’Neil from Lake Street assigned a Buy rating to Organogenesis Holdings (ORGO – Research Report), with a price target of $5.00. The company’s shares closed last Friday at $3.28. O’Neil covers the Healthcare sector, focusing on stocks such as Accuray, ModivCare, and Alphatec Holdings. According to TipRanks, O’Neil has an average return of 10.3% and a 49.45% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Organogenesis Holdings with a $4.25 average price target.

User Image Raque_Ellis Posted - 2 weeks ago

MYNZ 🔥 Perfect time to jump in, cheapest dip!!! Shorts volume increased. HUGE PR drop incoming before the Nov 13 meeting, so compliance is coming, no RS needed. Here is why… 1.Frankie Muniz backing Mainz (yes, the Malcolm guy & NASCAR #33 now repping MYNZ). 2.Petra, ex-Obama advisor, hinted at a big U.S. lab partner. Solid source! 3.Six news hits in 3 weeks—momentum. 4.Already solid in the EU, not new but expanding, with insurance covering their tests. 5.Their test has 88% accuracy vs. EXAS (42%) & GH (20%)—big edge! 6.$1.5M private placement in the bag. 7. CEO teased big plans ahead. 8.Offering Deal $ORGO $TEM

User Image biotechshrek Posted - 2 weeks ago

$ORGO this is going to grind much higher

User Image simonig1 Posted - 1 month ago

$XERS & $ORGO running Head to Head:

User Image Bakeface Posted - 1 month ago

$HUMA $ORGO

User Image simonig1 Posted - 1 month ago

$ORGO Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024 Link: https://investors.organogenesis.com/news-releases/news-release-details/organogenesis-holdings-inc-report-third-quarter-fiscal-year-2024

User Image josegodoy Posted - 1 month ago

$ORGO sales estimates?

User Image Bakeface Posted - 1 month ago

$ORGO $HUMA

User Image Invest2live Posted - 1 month ago

$ORGO 35% already; congrats 😊🎊🎈 Check out $ETN and $HTCR

Analyst Ratings
Lake Street Buy Jun 28, 24
Cantor Fitzgerald Overweight Mar 1, 24
Cantor Fitzgerald Overweight Feb 7, 24
BTIG Buy Dec 27, 23
Morgan Stanley Equal-Weight Nov 14, 23
Morgan Stanley Equal-Weight Aug 11, 23
BTIG Buy Aug 10, 23
Morgan Stanley Equal-Weight Jun 15, 23
BTIG Buy May 24, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
ERANI ALBERT 10% Owner 10% Owner Jan 09 Sell 4.32 215,893 932,658 59,007,134 01/11/24
ERANI ALBERT 10% Owner 10% Owner Apr 12 Sell 2.0709 25,000 51,772 59,223,027 04/14/23
Grow Brian Chief Commercial Off.. Chief Commercial Officer Aug 20 Option 1.46 805 1,175 87,744 08/24/22
Leibowitz Arthur S Director Director Aug 12 Buy 4.755 3,000 14,265 70,854 08/15/22
Driscoll Michael Joseph Director Director Aug 12 Buy 4.80 5,000 24,000 25,547 08/15/22
Gillheeney Gary S. President and CEO President and CEO Jun 30 Option 0.99 505,050 500,000 903,292 07/01/22
ERANI ALBERT 10% Owner 10% Owner Jun 09 Sell 5.1 30,000 153,000 59,248,027 06/13/22
ERANI ALBERT 10% Owner 10% Owner Jun 06 Sell 5.43 170,000 923,100 59,278,027 06/08/22
Gillheeney Gary S. President and CEO President and CEO May 26 Option 0.99 226,804 224,536 507,482 05/31/22
Gillheeney Gary S. President and CEO President and CEO May 26 Sell 5.77 226,804 1,308,659 398,242 05/31/22
Gillheeney Gary S. President and CEO President and CEO May 23 Option 0.99 197,336 195,363 482,916 05/25/22
Gillheeney Gary S. President and CEO President and CEO May 23 Sell 5.73 197,336 1,130,735 398,242 05/25/22
Gillheeney Gary S. President and CEO President and CEO May 18 Option 0.99 263,689 261,052 456,896 05/20/22
Gillheeney Gary S. President and CEO President and CEO May 18 Sell 5.76 263,689 1,518,849 398,242 05/20/22
KATZ MICHAEL W 10% Owner 10% Owner May 16 Buy 6.03 10,000 60,300 70,382 05/18/22
Gillheeney Gary S. President and CEO President and CEO May 13 Option 0.99 314,837 311,689 496,320 05/17/22
Gillheeney Gary S. President and CEO President and CEO May 13 Sell 6.02 314,837 1,895,319 398,242 05/17/22
Montecalvo Antonio S. Vice President, Heal.. Vice President, Health Policy Mar 09 Option 3.46 68,504 237,024 141,725 03/11/22
Montecalvo Antonio S. Vice President, Heal.. Vice President, Health Policy Mar 09 Sell 8.46 107,436 908,909 44,289 03/11/22
KATZ MICHAEL W 10% Owner 10% Owner Dec 02 Buy 9.55 2,600 24,830 59,882 12/06/21
KATZ MICHAEL W 10% Owner 10% Owner Nov 26 Buy 9.79 2,000 19,580 56,282 11/30/21